133 Molesworth Street
PO Box 5013
Wellington 6140
New Zealand
T +64 4 496 2000
W www.medsafe.govt.nz
18 January 2024
R Kingi
By email: [FYI request #25103 email]
Ref:
H2023033865
Tēnā koe,
Response to your request for official information
Thank you for your request under the Official Information Act 1982 (the Act) to the Ministry of
Health - Manatū Hauora (the Ministry) on 9 December 2023 for:
“
Recently there has been publication of an article detailing so called ribosomal frameshifting
in products that incorperate N1-methylpseudouridine into the modified mRNA, e.g. the
pfizer covid vaccine.
This concern was raised in 2021 so obviously it is a risk that competent scientists could
flag, however it was largely ignored at the time.
Please detail all internal communications around frameshifting as a potential risk, or area of
reasonable concern. If it was not considered a potential risk, please detail internal
communications that lead to it being dismissed as a risk, and how that conclusion was
drawn. “
Your request is refused under section 18(g)(i) as the information requested is not held by the
Ministry and there are no grounds for believing it is held by another agency subject to the Act.
Documents relating to the approval of Comirnaty, which may be of interest to you, have been
previously released at the following link:
www.health.govt.nz/system/files/documents/information-release/h202106950_-_response.pdf.
If you wish to discuss any aspect of your request with us, including this decision, please feel free
to contact the OIA Services Team
on: [email address].
Under section 28(3) of the Act, you have the right to ask the Ombudsman to review any decisions
made under this request. The Ombudsman may be contacted by email at:
[email address] or by calling 0800 802 602.
Please note that this response, with your personal details removed, may be published on the
Manatū Hauora website at:
www.health.govt.nz/about-ministry/information-releases/responses-
official-information-act-requests. Nāku noa, nā
Chris James
Group Manager
Medsafe
Page 2 of 2